

**Contact Information:**

Kristy Marks  
[Kristy.Marks@bausch.com](mailto:Kristy.Marks@bausch.com)  
908-927-0683

**Media Contact:**

Ashley Paskalis  
[Ashley.Paskalis@syneoshealth.com](mailto:Ashley.Paskalis@syneoshealth.com)  
212-845-5620

**ORTHO DERMATOLOGICS LAUNCHES FIRST  
CASH-PAY PRESCRIPTION PROGRAM IN DERMATOLOGY**

**Program Will Increase Patient Access to High Quality Dermatology Brands for Certain Conditions That Typically Face Insurance Challenges and High Prescription Costs**

**No Insurance, Copays, or Prior Authorizations Needed**

RALEIGH, N.C., Feb. 27, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced today the launch of an innovative cash-pay prescription program that will make many branded products available directly to patients with a valid prescription only – no insurance, co-pays or prior authorizations needed. The program is specifically designed to provide physicians and patients with direct access to a range of proven treatment options for certain disease states that typically encounter insurance coverage hassles and high prescription costs including acne, actinic keratosis (AK), superficial basal cell carcinoma (sBCCs), barrier repair (e.g. eczema treatments), wounds and corticosteroid-responsive diseases (CRDs) like rashes, psoriasis, and atopic dermatitis (AD).

“We have heard the same concern from dermatologists over and over. They work with their patients to develop treatment plans for common conditions – such as acne or corticosteroid-responsive diseases – only to encounter barriers, such as coverage denials, high co-pays, or prior authorization challenges that can lead to patients abandoning treatment,” said Bill Humphries, president, Ortho Dermatologics. “Our cash-pay prescription program is a new approach that gives patients access to proven brand medicines at predictable prices, simplifying the process of getting the medicines they know and trust, without needing to navigate the complexity of insurance.”

Approximately 86 percent of doctors say the burden imposed by the prior authorization process has increased over the last five years.<sup>1</sup> More troubling is a recent survey in which 78 percent of doctors reported that the need for prior authorization could sometimes lead to patients abandoning treatment.<sup>1</sup> The cash-pay prescription program eliminates these hurdles, because no insurance of any kind is accepted, which can help ensure a patient’s access to treatment.

“As a dermatologist, I achieve the best results for patients when I work closely with them and select treatments suited to their specific needs,” said Mark Kaufmann, M.D., dermatologist and associate clinical professor, Mount Sinai Health System, New York, New York. “When insurance protocols get in the way of those decisions, it’s frustrating for me and can be very discouraging for my patients. With Ortho Dermatologics’ predictable cash-pay prescription program, I can be confident that the specific

---

<sup>1</sup>American Medical Association 2017 Survey on Impact of PAs <https://www.ama-assn.org/sites/default/files/media-browser/public/arc/prior-auth-2017.pdf>

medications I prescribe end up being part of my patient's actual treatment plan, which I believe will ultimately help lead to improved outcomes for my patients."

Through the cash-pay prescription program, all patients, regardless of their insurance status, will be able to purchase medicines at prices ranging from \$50 - \$115. By doing so, the program will provide branded options that offer proven medicines with straightforward access. It will include some of the company's iconic dermatology brands, like Retin-A® (tretinoin) cream, as well as novel products from Ortho Dermatologics, such as ALTRENO™ (tretinoin) Lotion, 0.05%, which received approval from the U.S. Food & Drug Administration (FDA) in August 2018. ALTRENO Lotion is available to patients at \$115 for up to a three-month supply, or roughly \$40 per month.

Ortho Dermatologics plans to include approximately 20 products in the cash-pay patient program over the next 18 months, including some investigational therapies that will be added as soon as they become approved by the FDA.

The products available through the program at launch will include:

- Aldara® (imiquimod) 5% Cream - \$85\*
- ALTRENO™ (tretinoin) Lotion, 0.05% - \$115\*
- ATOPICLAIR® Non-Steroidal Cream - \$75\*
- Benzamycin® Topical Gel (erythromycin-benzoyl peroxide gel) - \$75\*
- BIAFINE® Emulsion Topical Cream - \$50\*
- Efudex® (fluorouracil) Topical Cream, 5% - \$85\*
- Locoid Lipocream® (hydrocortisone butyrate) Cream 0.1% - \$75\*
- Retin-A® (tretinoin) Cream - \$95\*

All products included in the cash-pay prescription program will be eligible for Flexible Spending Accounts or Health Saving Accounts and will continue to be supported by the company's Patient Assistance Program, which offers free medication for patients who meet income and other eligibility criteria.

### **About Ortho Dermatologics**

Ortho Dermatologics is one of the largest prescription dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and corticosteroid-responsive dermatoses products. More information can be found at [www.ortho-dermatologics.com](http://www.ortho-dermatologics.com).

### **Forward-looking Statements**

This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time

to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

\*All prices are MSRP (guaranteed only through MedVantx Pharmacy). No insurance benefits, including private insurance, Medicaid, Medicare, Tricare or any other federal or state healthcare programs (including any state prescription drug assistance programs) and the Government Health Insurance Plan available in Puerto Rico, can be used in conjunction with this program.

#### References

1. American Medical Association. 2017 Survey on Impact of PAs. Retrieved from <https://www.ama-assn.org/sites/default/files/media-browser/public/arc/prior-auth-2017.pdf>. Accessed February 1, 2018.

###

*Locoid Lipocream is a trademark of LEO PHARMA A/S used under license.  
All other ®/™ are trademarks of Ortho Dermatologics' affiliated entities.  
© 2019 All Rights Reserved.  
ORD.0085.USA.19*